Patient demographics and clinical characteristics of entire cohort at time of therapeutic drug monitoring for vedolizumab
| n=73 | |
| Median age, years (IQR) | 35.6 (28.9–56.4) |
| Male gender, n (%) | 39 (53.4) |
| Median disease duration, years (IQR) | 12.0 (7.0–18.9) |
| Diagnosis of CD, n (%) | 43 (58.9) |
| Active smoking, n (%) | 8 (11.0) |
| Previous anti-TNF exposure, n (%) | 40 (54.8) |
| Concomitant immunomodulator, n (%) | 15 (20.5) |
| Median duration on vedolizumab, years (IQR) | 1.6 (0.8–2.2) |
| Dosing regimen, n (%) | |
| 8 weekly | 59 (80.8) |
| 4 weekly | 14 (19.2) |
| Median trough vedolizumab level, µg/mL (IQR) | 10.6 (7.9–16.1) |
| Median BMI (IQR) | 25.4 (22.5–29.7) |
| Median albumin, g/dL (IQR) | 36.0 (34.0–38.0) |
| Median CRP, mg/L (IQR) | 4.0 (2.0–8.3) |
| Median FC, µg/g (IQR) | 182.0 (54.0–569.0) |
BMI, body mass index; CRP, C-reactive protein; FC, faecal calprotectin; TNF, tumour necrosis factor.